Rajvir Dahiya

Rajvir Dahiya holds Ph.D. in Experimental Medicine from Post Graduate Institute of Medical Education and Research Chandigarh, India, post-doctoral fellowship in medical oncology research from the University of Chicago Pritzker School of Medicine, M.D. from the Kagoshima University Faculty of Medicine, Kagoshima, Japan and D.Sc. from the Osaka University Graduate School of Medicine, Osaka, Japan. He became director of Oncology Urology Oncology Research Center at the UCSF/VAMC in 1991. After 34 years of service, he retired as a Professor Emeritus and Director of Urology Research Center. Dahiya has published more than 550 original research manuscripts. Dahiya’s world ranking in medicine is 4759 and USA ranking is 2644 with more than 35,500 research citations and D-index of 107 in 2024. He has written books and holds multiple patents in oncology. Based on the NIH and VA data base NIH Reporter and Grantome, Dahiya's research programs were supported (99 times awarded) by the NIH and VA. Dahiya is a founder and CEO of Geneverify Inc. focused on creation of in vitro mRNA genomic based diagnostic tests for cancer screening, early diagnosis, prognosis, and treatment follow-up. Geneverify is also working on developing novel medical technologies that target oncogenes, aiming to provide the most effective and highly specific treatments for various cancers, potentially saving the lives of millions of cancer patients. Currently, he is an associate editor of “Clinical Cancer Research” journal.